Dorzolamide

Carbonic Anhydrase Inhibitor — Ophthalmology

• Drug Class: Carbonic Anhydrase Inhibitor
• Category: Ophthalmology
• Type: Small Molecule
• SMILES: CCNC1CC(S(N)(=O)=O)c2cc(S(N)(=O)=O)ccc2S1(=O)=O

What is Dorzolamide?

Dorzolamide is a potent medication primarily used in the field of ophthalmology to manage elevated intraocular pressure (IOP), a key risk factor for glaucoma. As a member of the carbonic anhydrase inhibitor class, it exerts its therapeutic effect by reducing the production of aqueous humor within the eye. Available primarily as a topical ophthalmic solution, dorzolamide plays a crucial role in preventing optic nerve damage and preserving vision in patients with various forms of glaucoma and ocular hypertension. While commonly recognized by its generic name, it is also marketed under various brand names, with Trusopt^® being one of the most prominent. Understanding its pharmacological profile, clinical applications, and safety considerations is essential for healthcare providers involved in eye care.

Glaucoma is a group of progressive optic neuropathies characterized by damage to the optic nerve, often associated with elevated IOP. If left untreated, it can lead to irreversible vision loss and blindness. Dorzolamide offers a vital therapeutic option for lowering IOP, thereby slowing or halting the progression of this debilitating disease. Its mechanism of action, targeting a specific enzyme involved in fluid production within the eye, distinguishes it from other classes of glaucoma medications.

Mechanism of Action

Dorzolamide functions as a topical carbonic anhydrase inhibitor. Carbonic anhydrase is an enzyme present in various tissues throughout the body, including the ciliary processes of the eye. In the ciliary body, carbonic anhydrase plays a critical role in the secretion of aqueous humor, the fluid that fills the anterior and posterior chambers of the eye and maintains intraocular pressure.

The enzyme catalyzes the reversible reaction between carbon dioxide and water to form carbonic acid, which then dissociates into bicarbonate ions and protons:

CO₂ + H₂O <=> H₂CO₃ <=> H⁺ + HCO₃^-

Bicarbonate ions (HCO₃^-) are actively transported out of the ciliary epithelial cells into the posterior chamber. This transport drives the secretion of aqueous humor. By inhibiting carbonic anhydrase, dorzolamide reduces the formation of bicarbonate ions. This, in turn, decreases the active transport of sodium and bicarbonate into the posterior chamber, leading to a reduction in aqueous humor secretion. The net effect is a decrease in intraocular pressure.

Unlike oral carbonic anhydrase inhibitors, topical dorzolamide primarily acts locally within the eye, minimizing systemic side effects. The drug selectively inhibits carbonic anhydrase II, the predominant isoenzyme found in the ciliary processes, contributing to its efficacy and targeted action.

Clinical Uses & Indications

The primary indication for dorzolamide is the reduction of elevated intraocular pressure in patients with:

• Open-angle glaucoma: This is the most common type of glaucoma, where the drainage angle of the eye remains open, but the trabecular meshwork becomes less efficient at draining fluid.
• Ocular hypertension: This condition is characterized by elevated IOP without evidence of glaucomatous optic nerve damage or visual field loss. Patients with ocular hypertension are at increased risk of developing glaucoma.

Dorzolamide is approved by the U.S. Food and Drug Administration (FDA) for these indications. It can be used as monotherapy or as adjunctive therapy in combination with other IOP-lowering medications, such as beta-blockers (e.g., timolol) or prostaglandin analogs (e.g., latanoprost).

Combination Therapy

Fixed-combination eye drops containing dorzolamide and timolol (e.g., Cosopt^®) are widely prescribed for patients who require a greater reduction in IOP than can be achieved with monotherapy. This combination offers the benefits of both a carbonic anhydrase inhibitor and a beta-adrenergic blocking agent, providing a dual mechanism for lowering IOP.

The decision to use dorzolamide, either alone or in combination, is based on the individual patient's IOP, the severity of their glaucoma, their overall health status, and their response to previous treatments. Regular monitoring by an ophthalmologist is crucial to assess treatment effectiveness and manage potential side effects.

Dosage & Administration

Dorzolamide is formulated as a sterile ophthalmic solution for topical application to the eye. The typical concentration is 2% (20 mg/mL).

Standard Dosage

The usual dosage for adults is one drop instilled into the affected eye(s) three times daily (morning, midday, and evening).

Administration Instructions

To ensure proper administration and minimize contamination:

• Wash hands thoroughly before use.
• Tilt the head back and gently pull down the lower eyelid to create a small pocket.
• Hold the dropper bottle upside down and squeeze gently to release one drop into the pocket.
• Close the eye gently for about 1 minute, without blinking or squeezing the eyelids.
• Apply gentle pressure to the inner corner of the eye (nasolacrimal occlusion) for about 1 minute to minimize systemic absorption.
• Wipe away any excess solution from the face.
• Replace the cap securely after each use.

Missed Dose

If a dose is missed, it should be administered as soon as remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the dosing schedule should be resumed. Do not double the dose to catch up.

Special Populations

Dosage adjustments are generally not required for elderly patients. However, caution should be exercised in patients with impaired renal or hepatic function, as dorzolamide is excreted via the kidneys.

Side Effects & Safety

Like all medications, dorzolamide can cause side effects, although not everyone experiences them. The majority of side effects are mild and localized to the eye.

Common Side Effects

The most frequently reported side effects include:

• Ocular burning or stinging: A transient sensation upon instillation is common.
• Bitter or metallic taste: This can occur due to drainage of the medication through the nasolacrimal duct into the pharynx.
• Redness of the eye (conjunctival hyperemia).
• Blurred vision.
• Tearing (lacrimation).
• Foreign body sensation.
• Headache.

Less Common but Serious Side Effects

While less frequent, some side effects require immediate medical attention:

• Allergic reactions: Symptoms may include rash, itching, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing.
• Ocular side effects: Such as corneal edema, keratitis, eyelid inflammation (blepharitis), and sensitivity to light (photophobia).
• Systemic side effects: Although topical administration minimizes systemic absorption, rare instances of systemic effects similar to those seen with oral carbonic anhydrase inhibitors can occur. These may include fatigue, nausea, dizziness, and electrolyte imbalances (e.g., metabolic acidosis).

Contraindications

Dorzolamide is contraindicated in patients who are hypersensitive to any component of the medication, including sulfonamides. Due to its carbonic anhydrase inhibiting properties, it should also be used with caution or avoided in patients with:

• Severe renal impairment (creatinine clearance < 30 mL/min).
• Metabolic acidosis.
• Known hypersensitivity to sulfonamide derivatives.

Patients with a history of sulfonamide allergies should be closely monitored for signs of hypersensitivity reactions.

Drug Interactions

While dorzolamide is primarily applied topically, there is potential for systemic absorption, which can lead to drug interactions, particularly when used concurrently with other medications.

Interactions with Other Carbonic Anhydrase Inhibitors

Concomitant use of topical dorzolamide with systemic carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide) is generally not recommended due to the potential for additive pharmacologic effects and the increased risk of systemic side effects, including electrolyte imbalance, dehydration, and renal calculi.

Interactions with Medications Affecting pH or Electrolytes

Caution should be exercised when administering dorzolamide concurrently with drugs that can disrupt acid-base balance or electrolyte levels. This includes certain diuretics and other medications that may cause metabolic acidosis.

Interactions with Other Ophthalmic Medications

When using dorzolamide in conjunction with other topical ophthalmic agents, it is advisable to instill them at least 5 minutes apart to prevent dilution or interference with absorption. If using more than one type of eye drop, consult with a healthcare professional regarding the optimal administration sequence.

Potential for Systemic Absorption

It is important for patients to inform their healthcare provider about all medications they are currently taking, including over-the-counter drugs, herbal supplements, and other prescription medications, to identify any potential interactions. The risk of systemic side effects is higher in patients with impaired renal or hepatic function.

Molecular Properties

Understanding the molecular characteristics of dorzolamide is fundamental to appreciating its pharmacokinetic and pharmacodynamic properties.

• Molecular Formula: C₁₀H₁₆N₂O₄S₂
• Molecular Weight: 324.37 g/mol
• Chemical Name: (4S,6S)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 1,1-dioxide
• Structure Description: Dorzolamide is a sulfonamide derivative characterized by a thienothiopyran ring system. It features a sulfonamide group (-SO₂NH₂) attached to the heterocyclic ring, which is crucial for its interaction with the carbonic anhydrase enzyme. It also contains an ethylamino side chain. The molecule possesses chiral centers, leading to specific stereoisomers, with the (4S,6S) configuration being the pharmacologically active form. The SMILES notation for dorzolamide is: CCNC1CC(S(N)(=O)=O)c2cc(S(N)(=O)=O)ccc2S1(=O)=O. This representation precisely defines the connectivity and arrangement of atoms within the molecule, serving as a unique identifier for computational analysis and database searching.

The presence of the sulfonamide group is key to its mechanism of action, as it mimics the transition state of the carbonic anhydrase reaction and binds to the zinc ion in the enzyme's active site. The specific stereochemistry and arrangement of functional groups contribute to its selectivity and efficacy as a topical carbonic anhydrase inhibitor.

Analyze Dorzolamide with MolForge

The journey from identifying a promising molecule like dorzolamide to its widespread clinical use involves intricate research and development processes. Leveraging advanced AI-powered platforms can significantly accelerate these endeavors. MolForge offers a suite of sophisticated tools designed to empower researchers and pharmaceutical scientists in exploring molecular properties, predicting interactions, and optimizing drug candidates.

With MolForge, you can delve deeper into the chemical space surrounding dorzolamide. Our platform allows for detailed analysis of its structure, prediction of its physicochemical properties, and even exploration of potential off-target effects or novel therapeutic applications. By utilizing our AI-driven insights, you can gain a comprehensive understanding of dorzolamide's behavior and identify new avenues for drug discovery and development. Whether you are investigating lead optimization, designing novel analogs, or seeking to understand complex biological interactions, MolForge provides the computational power to drive innovation.

Ready to explore the future of molecular discovery? Visit our dashboard to harness the power of MolForge AI and unlock the potential of molecules like dorzolamide.